Category Archives: Business of Biotech

Raptor Pharmaceuticals Corp. and TorreyPines Therapeutics, Inc. complete merger

Raptor Pharmaceuticals Corp. (“Raptor”) (OTC Bulletin Board: RPTP) and TorreyPines Therapeutics, Inc. (“TorreyPines”) (Nasdaq: TPTX) announced the completion of their merger. The combined company is named “Raptor Pharmaceutical Corp.” and will commence trading today on the NASDAQ Capital Market under the ticker symbol “RPTP.” Pursuant to NASDAQ’s regulations, for the first 20 trading days the ticker symbol will be “RPTPd”. The combined company will be headquartered in Novato, California and managed by Raptor’s existing management Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

LifeCycle Pharma announces Phase 2 results for liver transplant patients study

LifeCycle Pharma A/S (CSE:LCP) announced positive results from a 12 month extension phase of the Phase 2 clinical study of LCP-Tacro tablets in stable liver transplant patients. LCP-Tacro is a once daily immunosuppression drug to prevent rejection after organ transplantation. These new data demonstrated that LCP-Tacro tablets for stable liver patients continues in the extension phase of the study to have a potential best-in-class profile when compared to the currently marketed twice daily tacrolimus capsule, Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

RegeneRx’s TB4 shows functional recovery in MS animal model

RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) announces significant improvement in neurological functional recovery after TB4 treatment of EAE (experimental autoimmune encephalomyelitis – an animal model for multiple sclerosis), according to Henry Ford Health System researchers. In addition, researchers reported a significant reduction of inflammation and induction of oligodendrogenesis (maturation of central nervous system cells associated with the formation of the nerve sheath). The study entitled, “Neurological Functional Recovery after Thymosin Beta 4 Treatment in Mice with Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Novelos announces $1 million NIH Grant

Novelos Therapeutics, Inc. (OTCBB: NVLT) was awarded a $950,371 competitive grant by the National Institutes of Health (NIH) for a collaborative study with Massachusetts General Hospital (MGH) on two Novelos compounds – NOV-002 and NOV-205 – for the mitigation and treatment of radiation-induced pulmonary injury. This 17-month grant will fund the assessment of both drug candidates in animal models designed to reflect pulmonary injury resulting from, for example, a terrorist incident involving a radiation-dispersal device Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Positive Results in Plague Study

Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) announced results from a primate study involving the oral antibiotic Restanza(TM) (cethromycin) demonstrating statistical significance at a 90% survival rate against an inhaled lethal dose of plague. The study tested Restanza’s protective efficacy at various doses up to 64 mg/kg, where nine out of ten animals in the study that received a 14-day course of Restanza initiated within 24 hours after exposure to a lethal dose Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,